By reducing acetylcholine activity in selected brain pathways, Artane helps ease tremor, muscle stiffness, and certain involuntary movements. It is used in adults with Parkinson’s disease or medication-related movement disorders when these symptoms interfere with daily function.
Artane helps ease tremor, muscle stiffness, and certain involuntary movements. Its active substance, trihexyphenidyl, is an anticholinergic that helps rebalance signalling involved in movement control.
Artane contains trihexyphenidyl, a centrally acting anticholinergic medicine used in neurology.
It does not replace dopamine, but reduces the relative influence of acetylcholine in movement-related brain circuits. This can lessen tremor, rigidity, excess salivation, and abnormal postures in suitable patients.
Trihexyphenidyl blocks muscarinic acetylcholine receptors. This dampens excessive cholinergic signalling and can improve muscle control when dopamine pathways are impaired. It may reduce stiff muscles and tremor, though it does not restore dopamine-producing nerve cells.
Movement becomes smoother when excessive acetylcholine activity is reduced. For some people, this means less pulling or twisting of a limb. For others, the change is a quieter resting tremor.
The benefit varies between individuals. Tremor may improve while walking speed changes little. This difference matters when setting expectations for treatment.
Artane may be prescribed for:
One detail patients often miss is overheating. Anticholinergic medicines can reduce sweating, so heat exposure may feel harder to tolerate even when the tablet itself has been used for some time.
Artane is not for you if you have narrow-angle glaucoma, because anticholinergic pupil dilation can raise pressure inside the eye. It is also unsuitable for people with known hypersensitivity to trihexyphenidyl.
Extra caution is needed with:
Artane can add to the effects of other medicines with anticholinergic properties, including some antidepressants, antihistamines, bladder medicines, and antipsychotics. Combining several such medicines can increase constipation, blurred vision, urinary retention, sedation, and confusion.
Talk with a clinician before using Artane if you have eye-pressure problems, difficulty urinating, severe constipation, memory problems, hallucinations, heart-rhythm concerns, or reduced sweating. Extra care is also needed during pregnancy or breastfeeding and if you take medicines that can cause drowsiness or anticholinergic effects.
Artane’s adverse effects reflect its anticholinergic action. Reduced saliva, slowed bowel activity, and relaxed bladder function can be useful in limited situations, yet they can also become troublesome.
Common effects include:
Central nervous system effects deserve close attention. Memory problems, reduced concentration, confusion, agitation, and hallucinations can occur, with risk rising in older adults and at higher individual doses. FDA prescribing information for trihexyphenidyl describes these anticholinergic effects and warns about impaired mental alertness. [1]
A dry mouth may sound minor, yet persistent dryness can affect eating, speaking, dentures, and dental comfort. Constipation can also build gradually rather than appearing on the first day.
Alcohol may worsen drowsiness, dizziness, and impaired judgement. Driving, cycling in traffic, or operating machinery can be unsafe until the individual response is known.
Artane is one approach within a broader treatment plan for Parkinsonism and drug-induced movement disorders. The preferred option depends on the symptom pattern, age, cognition, and the medicine causing the movement problem.
| Treatment approach | Main mechanism | Clinical role |
|---|---|---|
| Trihexyphenidyl | Central muscarinic receptor blockade | Tremor, rigidity, and selected drug-induced movement symptoms |
| Biperiden | Central anticholinergic action | Similar use when an anticholinergic is appropriate |
| Dopaminergic therapy | Enhances or replaces dopamine signalling | Broader Parkinson’s symptom management under neurological care |
Dopaminergic treatment often has a larger role in Parkinson’s disease, especially where slowness of movement affects function. Anticholinergic therapy has a narrower place because cognitive and peripheral adverse effects may outweigh tremor benefit for some people.
The European Medicines Agency’s guidance on Parkinson’s disease studies reflects this symptom-specific approach: treatment effect should be judged against meaningful motor outcomes and tolerability, rather than expecting one medicine to improve every Parkinsonian feature equally. [2]
In clinical practice, prescribers often reserve Artane for people whose tremor, stiffness, or medicine-induced involuntary movements remain disruptive despite adjustment of the wider treatment plan. The target is functional improvement: holding a cup steadily, writing more easily, or reducing painful muscle pulling.
Doctors also watch for the trade-off. A person may report less tremor but develop dry mouth, constipation, fuzzy vision, or forgetfulness. When that happens, the best response is often reassessing the dose or the treatment plan rather than simply adding more medicines.
Older adults require extra care. Anticholinergic burden can accumulate across several prescriptions, and a new episode of confusion may be medicine-related rather than a sudden change in the neurological condition.
Yes. Artane can dilate the pupil and may raise eye pressure in people with narrow-angle glaucoma, which can trigger an acute eye emergency. Severe eye pain, halos around lights, sudden blurred vision, headache, or nausea need urgent medical assessment. The FDA prescribing information for trihexyphenidyl lists narrow-angle glaucoma as a contraindication in its 2017 document.
Stopping can allow tremor, stiffness, dystonia, or medication-related involuntary movements to return. After regular use, clinicians commonly reduce treatment gradually instead of stopping abruptly, especially when symptoms have been controlled for a long period. The WHO’s 2023 Model List places anticholinergics within management of extrapyramidal adverse effects, so withdrawal planning should account for the condition being treated.
Some people notice reduced stiffness or tremor within days, while others need a longer adjustment period as the individualized regimen is established. Improvement is usually judged by practical changes, such as easier writing, less painful muscle pulling, or reduced resting tremor. A 2003 Cochrane review found symptomatic benefit in Parkinsonism, though responses differed between participants and adverse effects limited use for some people.
The best timing is the schedule set for the individual prescription, with doses taken consistently from day to day. If drowsiness occurs, a clinician may consider whether timing contributes; if it causes wakefulness or restlessness, that pattern also matters. Health Canada’s 2025 Drug Product Database supports the use of approved product information when reviewing administration and medicine-specific precautions.
Mention glaucoma, urinary difficulties, constipation, bowel disease, heart rhythm problems, memory concerns, hallucinations, and all medicines that can cause drowsiness or anticholinergic effects. Also discuss work that involves driving, heights, machinery, or tasks requiring sharp visual focus. EMA guidance published in 2012 emphasizes meaningful assessment of motor benefit and treatment tolerability in Parkinson’s disease, which is why both symptom goals and cognitive risk should be reviewed before treatment begins.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
My hand tremor eased gradually after the dose was adjusted. The dry mouth was annoying at work, but sugar-free lozenges helped. I noticed I could type without stopping to shake out my fingers.
The neck tightness settled within the first part of treatment and I slept better because the spasms were not waking me. I had mild blurred vision one evening, so I avoided driving until it passed.
The resting tremor was less obvious when I was sitting, which made meals easier. It did not do much for my slower walking, but that was explained before I started.
It helped the pulling sensation, but constipation became a problem in week two. My prescriber changed the plan rather than having me push through it.
I stopped because I felt forgetful and more foggy in the afternoon. The tremor benefit was there, but it was not enough to outweigh the concentration issue for me.
